142 related articles for article (PubMed ID: 12446128)
1. Alzheimer's and prion diseases: distinct pathologies, common proteolytic denominators.
Checler F; Vincent B
Trends Neurosci; 2002 Dec; 25(12):616-20. PubMed ID: 12446128
[TBL] [Abstract][Full Text] [Related]
2. Regulation of betaAPP and PrPc cleavage by alpha-secretase: mechanistic and therapeutic perspectives.
Vincent B; Cisse MA; Sunyach C; Guillot-Sestier MV; Checler F
Curr Alzheimer Res; 2008 Apr; 5(2):202-11. PubMed ID: 18393805
[TBL] [Abstract][Full Text] [Related]
3. ADAM proteases: protective role in Alzheimer's and prion diseases?
Vincent B
Curr Alzheimer Res; 2004 Aug; 1(3):165-74. PubMed ID: 15975064
[TBL] [Abstract][Full Text] [Related]
4. The P's and Q's of cellular PrP-Aβ interactions.
Westaway D; Jhamandas JH
Prion; 2012; 6(4):359-63. PubMed ID: 22874673
[TBL] [Abstract][Full Text] [Related]
5. Games played by rogue proteins in prion disorders and Alzheimer's disease.
Aguzzi A; Haass C
Science; 2003 Oct; 302(5646):814-8. PubMed ID: 14593165
[TBL] [Abstract][Full Text] [Related]
6. Roles of endoproteolytic α-cleavage and shedding of the prion protein in neurodegeneration.
Altmeppen HC; Prox J; Puig B; Dohler F; Falker C; Krasemann S; Glatzel M
FEBS J; 2013 Sep; 280(18):4338-47. PubMed ID: 23413979
[TBL] [Abstract][Full Text] [Related]
7. Taking advantage of physiological proteolytic processing of the prion protein for a therapeutic perspective in prion and Alzheimer diseases.
Béland M; Roucou X
Prion; 2014; 8(1):106-10. PubMed ID: 24335160
[TBL] [Abstract][Full Text] [Related]
8. High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease.
Dohler F; Sepulveda-Falla D; Krasemann S; Altmeppen H; Schlüter H; Hildebrand D; Zerr I; Matschke J; Glatzel M
Brain; 2014 Mar; 137(Pt 3):873-86. PubMed ID: 24519981
[TBL] [Abstract][Full Text] [Related]
9. Microbiome Influence in the Pathogenesis of Prion and Alzheimer's Diseases.
D'Argenio V; Sarnataro D
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31547531
[TBL] [Abstract][Full Text] [Related]
10. Decoding the function of the N-terminal tail of the cellular prion protein to inspire novel therapeutic avenues for neurodegenerative diseases.
Iraci N; Stincardini C; Barreca ML; Biasini E
Virus Res; 2015 Sep; 207():62-8. PubMed ID: 25456402
[TBL] [Abstract][Full Text] [Related]
11. Pathogenic mechanisms of prion protein, amyloid-β and α-synuclein misfolding: the prion concept and neurotoxicity of protein oligomers.
Ugalde CL; Finkelstein DI; Lawson VA; Hill AF
J Neurochem; 2016 Oct; 139(2):162-180. PubMed ID: 27529376
[TBL] [Abstract][Full Text] [Related]
12. Roles of proteolysis and lipid rafts in the processing of the amyloid precursor protein and prion protein.
Hooper NM
Biochem Soc Trans; 2005 Apr; 33(Pt 2):335-8. PubMed ID: 15787600
[TBL] [Abstract][Full Text] [Related]
13. Evolving views in prion glycosylation: functional and pathological implications.
Ermonval M; Mouillet-Richard S; Codogno P; Kellermann O; Botti J
Biochimie; 2003; 85(1-2):33-45. PubMed ID: 12765773
[TBL] [Abstract][Full Text] [Related]
14. Interaction of Peptide Aptamers with Prion Protein Central Domain Promotes α-Cleavage of PrP
Corda E; Du X; Shim SY; Klein AN; Siltberg-Liberles J; Gilch S
Mol Neurobiol; 2018 Oct; 55(10):7758-7774. PubMed ID: 29460268
[TBL] [Abstract][Full Text] [Related]
15. Combined pharmacological, mutational and cell biology approaches indicate that p53-dependent caspase 3 activation triggered by cellular prion is dependent on its endocytosis.
Sunyach C; Checler F
J Neurochem; 2005 Mar; 92(6):1399-407. PubMed ID: 15748158
[TBL] [Abstract][Full Text] [Related]
16. Sialylated glycosylphosphatidylinositols suppress the production of toxic amyloid-β oligomers.
Nolan W; McHale-Owen H; Bate C
Biochem J; 2017 Aug; 474(17):3045-3058. PubMed ID: 28729427
[TBL] [Abstract][Full Text] [Related]
17. Aβ induces its own prion protein N-terminal fragment (PrPN1)-mediated neutralization in amorphous aggregates.
Béland M; Bédard M; Tremblay G; Lavigne P; Roucou X
Neurobiol Aging; 2014 Jul; 35(7):1537-48. PubMed ID: 24602510
[TBL] [Abstract][Full Text] [Related]
18. The sheddase ADAM10 is a potent modulator of prion disease.
Altmeppen HC; Prox J; Krasemann S; Puig B; Kruszewski K; Dohler F; Bernreuther C; Hoxha A; Linsenmeier L; Sikorska B; Liberski PP; Bartsch U; Saftig P; Glatzel M
Elife; 2015 Feb; 4():. PubMed ID: 25654651
[TBL] [Abstract][Full Text] [Related]
19. Alzheimer's disease.
De-Paula VJ; Radanovic M; Diniz BS; Forlenza OV
Subcell Biochem; 2012; 65():329-52. PubMed ID: 23225010
[TBL] [Abstract][Full Text] [Related]
20. Delineating common molecular mechanisms in Alzheimer's and prion diseases.
Barnham KJ; Cappai R; Beyreuther K; Masters CL; Hill AF
Trends Biochem Sci; 2006 Aug; 31(8):465-72. PubMed ID: 16820299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
